The global blood glucose monitor market is poised for substantial growth as the burden of diabetes continues to rise worldwide. The market is projected to expand from USD 16.46 billion in 2025 to USD 25.41 billion by 2030, registering a CAGR of 9.1% during the forecast period.
Growing cases of diabetes and prediabetes, coupled with sedentary lifestyles, unhealthy eating habits, and aging populations, are significantly increasing the demand for reliable glucose monitoring solutions. Technological advancements in continuous glucose monitoring (CGM), increasing awareness of diabetes management, and improving healthcare access in developing economies are further accelerating market growth.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14912252
Rising Diabetes Burden Fuels Demand for Glucose Monitoring
Diabetes remains one of the fastest-growing chronic diseases globally, making regular blood glucose monitoring an essential part of disease management. Healthcare providers are increasingly recommending continuous and self-monitoring blood glucose devices to help patients maintain optimal glycemic control, reduce complications, and improve overall quality of life.
The adoption of continuous glucose monitoring (CGM) systems has grown rapidly due to their ability to provide real-time glucose readings without frequent fingerstick testing. These devices enable patients and clinicians to make faster treatment decisions while improving long-term diabetes outcomes.
However, despite strong market momentum, challenges such as the high cost of advanced CGM systems, affordability concerns among lower-income populations, and limited reimbursement coverage in certain regions continue to restrain wider adoption.
Innovation Driving the Next Generation of Diabetes Care
Leading manufacturers are continuously introducing advanced monitoring technologies to improve accuracy, convenience, and patient engagement.
In April 2025, DexCom, Inc. received US FDA approval for its DexCom G7 15-Day Continuous Glucose Monitoring System, designed for adults aged 18 years and older with diabetes. The extended wear period offers greater convenience while maintaining high accuracy.
Earlier, in June 2024, Abbott Laboratories received US FDA clearance for two over-the-counter continuous glucose monitoring systems—Lingo and Libre Rio. Built on Abbott’s widely adopted FreeStyle Libre technology, these products expand glucose monitoring beyond traditional diabetes management to support broader health and wellness applications.
These product innovations demonstrate the industry’s growing focus on making glucose monitoring more accessible, user-friendly, and digitally connected.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=14912252
Leading Companies Strengthening Market Leadership
Several multinational healthcare companies continue to shape the competitive landscape through continuous innovation and expanding product portfolios.
Abbott Laboratories (US) remains the global market leader with its highly successful FreeStyle Libre portfolio. Offering sensors, readers, test strips, and digital health platforms, Abbott has transformed diabetes management through real-time continuous glucose monitoring while expanding into preventive health with its Lingo platform.
DexCom, Inc. (US) has established itself as a leading innovator in continuous glucose monitoring through its DexCom G6 and G7 systems. Integrated with mobile applications and cloud-based data platforms, DexCom solutions provide patients and healthcare professionals with actionable glucose insights that support better disease management.
Medtronic (Ireland) continues to strengthen its diabetes care business through integrated insulin delivery and glucose monitoring solutions. Its MiniMed insulin pump systems, combined with Guardian CGM sensors, enable automated insulin delivery and move patients closer to fully closed-loop diabetes management.
Other major companies contributing to market growth include F. Hoffmann-La Roche Ltd. (Switzerland), Sinocare (China), B. Braun SE (Germany), and Ascensia Diabetes Care Holdings AG (Switzerland), each expanding their global presence through product innovation and improved accessibility.
Market Outlook
The blood glucose monitor market remains moderately consolidated, with the top five companies accounting for more than 55% of global market share. Industry leaders continue investing in continuous glucose monitoring technologies, artificial intelligence-enabled analytics, mobile health integration, and personalized diabetes management platforms.
Looking ahead, the market is expected to benefit from increasing diabetes screening programs, greater adoption of digital healthcare solutions, expanding reimbursement policies, and rising demand for remote patient monitoring. As continuous glucose monitoring becomes more affordable and accessible, the industry will play a pivotal role in improving diabetes care worldwide.
With ongoing technological advancements and increasing emphasis on preventive healthcare, the global blood glucose monitor market is well-positioned for sustained growth through 2030, delivering innovative solutions that empower patients to manage diabetes more effectively while enhancing clinical outcomes.